Follow-up of Osteo-articular Biomarkers After Spa Therapy in a Population With Knee Osteoarthritis and Their Correlation With the Clinical Evolution
BIOMARTHROSE
1 other identifier
interventional
37
1 country
1
Brief Summary
Spa therapy is used in the treatment of various diseases and mainly osteoarthritis. Knee osteoarthritis is a very common rheumatic disease whose prevalence increases with longer life span and is a public health problem. The Forestier and al. study highlighted the actual benefit and confirmed the improvement of the quality of life and pain of the knee osteoarthritis patients from 6 months of spa treatment.\[1\] A significant decrease of 30% in the rate of Serum Hyaluronic Acid at 6 months after the end of the spa therapy was also highlighted in the Canteloup et al study.\[6\] This study aims to measure different osteoarticular biomarkers (hyaluronic acid, coll2-1 and CTX1) before, at the end of the spa therapy and 6 months after the spa therapy and correlate with the clinical evaluation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable knee-osteoarthritis
Started Sep 2020
Typical duration for not_applicable knee-osteoarthritis
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 5, 2020
CompletedFirst Posted
Study publicly available on registry
March 16, 2020
CompletedStudy Start
First participant enrolled
September 15, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2023
CompletedJuly 3, 2023
June 1, 2023
2.8 years
March 5, 2020
June 30, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Describe the change of serum level of Hyaluronic acid (a marker of synovial inflammation)
Measure of serum level of Hyaluronic acid before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6).
6 months (timepoint: at Day 0, Week 3 and month 6)
Secondary Outcomes (6)
Marker of cartilage degradation: Coll2-1
6 months (timepoint: at Day 0, Week 3 and month 6)
Marker of bone resorption: CTX1
6 months (timepoint: at Day 0, Week 3 and month 6)
Index of symptomatic severity of knee osteoarthritis or WOMAC
6 months (timepoint: at Day 0, Week 3 and month 6)
Pain evaluation Visual Analogue Scale
6 months (timepoint: at Day 0, Week 3 and month 6)
SF 36 Quality of Life Questionnaire
6 months (timepoint: at Day 0, Week 3 and month 6)
- +1 more secondary outcomes
Study Arms (1)
Blood collection arm
OTHERBlood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6).
Interventions
Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
Eligibility Criteria
You may qualify if:
- Patient with knee osteoarthritis defined according to the recommendations of the American College of Rheumatology (ACR):
- painful articulation and at least one of the following three criteria: age \> 50 years and/or articular crepitation and/or morning stiffness less than 30min
- and radiographic sign of gonarthrosis with osteophyte (on X-rays of less than 3 years).
- Patient can come to the final visit at 6 months and living within a perimeter of 30km around Dax.
- Patient affiliated to a social security scheme.
You may not qualify if:
- Osteoarthritis limited to patellofemoral joint.
- A previous spa therapy of less than 6 months.
- Spa therapies with double indication rheumatology and phlebology.
- Patient with osteoporosis.
- A known hepatocellular failure or known acute or end-stage renal failure.
- Severe depressive syndrome, psychotic syndrome, immune deficiency, cardiopathy, evolutive neoplasia or infection.
- Infiltration and/or viscosupplementation \< 6 months.
- Change in anti-osteoarthritis treatment of less than 3 months.
- Patient under tutorship or curatorship.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
centre hospitalier Dax
Dax, 40100, France
Related Publications (1)
Forestier R, Desfour H, Tessier JM, Francon A, Foote AM, Genty C, Rolland C, Roques CF, Bosson JL. Spa therapy in the treatment of knee osteoarthritis: a large randomised multicentre trial. Ann Rheum Dis. 2010 Apr;69(4):660-5. doi: 10.1136/ard.2009.113209. Epub 2009 Sep 3.
PMID: 19734131RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Charles COWAN, MD
CH de Dax
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 5, 2020
First Posted
March 16, 2020
Study Start
September 15, 2020
Primary Completion
June 30, 2023
Study Completion
June 30, 2023
Last Updated
July 3, 2023
Record last verified: 2023-06